MLTX
MoonLake Immunotherapeutics
$18.73
+$1.65(+9.63%)
55
Overall
60
Value
50
Tech
--
Quality
Market Cap
$672.08M
Volume
1.35M
52W Range
$5.95 - $62.75
Target Price
$29.83
Company Overview
| Mkt Cap | $672.08M | Price | $18.73 |
| Volume | 1.35M | Change | +9.63% |
| P/E Ratio | -5.7 | Open | $17.38 |
| Revenue | -- | Prev Close | $17.08 |
| Net Income | $-118.9M | 52W Range | $5.95 - $62.75 |
| Div Yield | N/A | Target | $29.83 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies. The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest News
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
Christine Brown•8 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MLTX | $18.73 | +9.6% | 1.35M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get MoonLake Immunotherapeutics Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW